GUILFORD, Conn.–(Business Wire)– Bioasis Technologies Inc. (TSX.V:BTI)(OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (BBB) and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that members of management will present at the following… Read more »
Nov. 20, 2018 Bioasis Announces Positive Results from Peripheral Whole-Body PET/CT Scan Study in Non-Human Primates with Lead Investigational Candidate xB3-001™
xB 3 -001 demonstrated lymphatic system penetration and more selective tissue distribution with xB 3 -001 than trastuzumab alone The Company has filed patent applications based on these observations and those data may have broader applicability An updated version of the corporate presentation is available for review at www.bioasis.us/investors
Bioasis will present at the 25th Annual BIO International Convention, to be held June 4-7, 2018 at the Boston Convention & Exhibition Center.
VANCOUVER, British Columbia & GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that it will present at the 20th Annual BIO CEO & Investor Conference, to be held February 12-13, 2018 at the New York Marriott Marquis. Mark Day, Ph.D., president and chief executive officer, Bioasis, will present at the BIO CEO &… Read more »
Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that it will present at the Biotech Showcase™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, the chief executive officer of biOasis, will present at the Global Chinese Financial Forum (GCFF) – Shanghai Conference 2017, in Shanghai, China, on June 22, 2017. biOasis Board Chairman, Rob Hutchison, will attend the conference with Dr. Day. Dr. Day’s presentation,… Read more »
Jun. 4, 2017 biOasis to Present at the 16th International Postgraduate Course on Lysosomal Storage Disorders
VANCOUVER, BC–(Business Wire)– Bioasis Technologies, Inc. (OTCQB:BIOAF; TSX.V:BTI) announced today that Dr. Mark Day, chief executive officer, will present at the 16th International Postgraduate Course on Lysosomal Storage Disorders, in Nierstein (Mainz), Germany on June 07–10, 2017. Dr. Day’s presentation, “Improving the Probability of Success in CNS Drug Discovery and Development: A Case Study,” targets… Read more »
May. 17, 2016 biOasis Technologies Inc. to Present at BIO International Conference in San Francisco on June 7, 2016
biOasis to showcase their Transcend technology for the transport of drugs across the blood-brain barrier (BBB)
Apr. 3, 2014 biOasis Presents Results From Its BT2111 Program at International Cancer Research Conference
biOasis and collaborators from Alexandria University, Egypt; Texas Tech University HSC, Amarillo, Texas and; the West Virginia University HSC, School of Pharmacy, Morgantown, WV; Presents Progress in Developing a Novel Therapy to Treat Brain Metastases of Breast Cancer
Oct. 18, 2013 biOasis Presents Research Results on BT2111 (Transcend-Trastuzumab) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX:V BTI) is pleased to announce that preclinical data on its proprietary BT2111 program will be presented during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held in Boston, MA from October 19-23, 2013. biOasis’ presentation entitled “BT2111, a new anticancer agent composed of trastuzumab… Read more »